Stock Analysis: Acme Packet, Gilead Science, Amgen, Brightpoint

Acme Packet, Inc.(NASDAQ:APKT): Jefferies believes Acme Packet’s below consensus 2012 guidance is very conservative and recommends buying the stock aggressively on today’s weakness. The firm maintains a Buy rating on the name with a $35 price target.

Sequenom Inc.(NASDAQ:SQNM): Piper Jaffray believes the Genetics in Medicine article showing Sequenom’s MaterniT21’s ability to accurately detect trisomy 13 and 18 should alleviate concerns of the test’s ability to detect rarer chromosomal abnormalities. The firm keeps an Overweight rating on Sequenom shares with a $6.25 price target.

Gilead Sciences Inc.(NASDAQ:GILD): Deutsche Bank calls Gilead the best growth story in biotech following the company’s Q4 results and cites increased confidence in the company’s Hepatitis C virus program for its increased price target. The firm maintains a Buy rating on the stock.

Amgen Inc.(NASDAQ:AMGN): Deutsche Bank likes the risk/reward on Amgen shares into the February 8 FDA panel discussing Xgeva for the prevention of bone mets in high-risk prostate cancer. The firm sees shares upside potential of $1.50-$3.00 but keeps a Hold rating on the stock.

Brightpoint Inc.(NASDAQ:CELL): Citigroup views the sell-off yesterday post Brightpoint’s Q4 results as a buying opportunity and keeps a Buy rating on the stock with a $13.50 price target.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at